Author:
van Luin Matthijs,Gras Luuk,Richter Clemens,van der Ende Marchina E,Prins Jan M,Wolf Frank de,Burger David M,Wit Ferdinand W
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
Pharmacology (medical),Infectious Diseases
Cited by
32 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Safety of low dose efavirenz regimen in Indian adults with HIV-1 infection: Insights from a phase 4 interventional randomised trial;Medicine;2023-11-03
2. Therapeutic drug monitoring study on the switch from coformulated 600-mg efavirenz, tenofovir disoproxil fumarate, and emtricitabine to coformulated 400-mg efavirenz, tenofovir disoproxil fumarate, and lamivudine among HIV-positive patients with viral suppression;J MICROBIOL IMMUNOL;2021
3. Therapeutic drug monitoring study on the switch from coformulated 600-mg efavirenz, tenofovir disoproxil fumarate, and emtricitabine to coformulated 400-mg efavirenz, tenofovir disoproxil fumarate, and lamivudine among HIV-positive patients with viral suppression;Journal of Microbiology, Immunology and Infection;2021-10
4. Pharmacodynamics of efavirenz 400 mg in treatment-naïve Chinese HIV-infected patients in a prospective cohort study;BMC Infectious Diseases;2021-01-23
5. Effectiveness of half-a-tablet efavirenz plus 2 nucleos(t)ide reverse-transcriptase inhibitors as maintenance therapy with the guidance of therapeutic drug monitoring among virologically suppressed HIV-positive patients: A prospective study;Journal of Microbiology, Immunology and Infection;2020-02